Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wissam Gharib

Interventional Cardiology Morgantown, WV Medical Doctor

NPI 1386757037 CMS profile 198394

2000 Mon Health Medical Park Dr Ste 2300, Morgantown, WV 26505

Open in the dashboard

General payments

$178,736

977 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$371,159 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Wissam Gharib of Morgantown, WV is reported in the CMS Open Payments database as having received $178,736 across 977 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $371,159 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $35,833 253
2024 General $14,371 176
2023 General $35,213 154
2022 General $10,995 120
2021 General $15,832 84
2020 General $35,243 82
2019 General $31,250 108

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wissam Gharib
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Wissam Gharib were reported at $35,833. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Wissam Gharib Interventional Cardiology median Middle half National median
2019 $31,250 $1,097 $329–$3,048 $163
2020 $35,243 $473 $161–$1,480 $114
2021 $15,832 $677 $233–$1,827 $132
2022 $10,995 $978 $333–$2,724 $149
2023 $35,213 $1,136 $382–$2,986 $160
2024 $14,371 $1,181 $395–$3,326 $164
2025 $35,833 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $97,136 214 payments
  2. Recor Medical Inc $14,288 48 payments
  3. Shockwave Medical, Inc $13,246 28 payments
  4. Edwards Lifesciences Corporation $11,972 71 payments
  5. Bard Peripheral Vascular, Inc. $8,576 27 payments
  6. Biotronik Inc. $7,155 15 payments
  7. Abbott Laboratories $6,974 91 payments
  8. Medtronic, Inc. $4,417 96 payments
  9. Philips Electronics North America Corporation $2,796 7 payments
  10. Terumo Medical Corporation $1,796 18 payments
  11. Other $10,382 362 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $55,275 20 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $53,543 14 payments
  3. Food and Beverage $36,296 855 payments
  4. Travel and Lodging $24,815 82 payments
  5. Compensation for serving as faculty or as a speaker for a medical education program $8,800 4 payments
  6. Education $7 2 payments
Products named General payments · program years 2019–2025
  1. WATCHMAN Structural Heart $34,672 42 payments
  2. WATCHMAN Access System $22,009 38 payments
  3. GENERAL - STRUCTURAL HEART $13,693 1 payment
  4. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $12,714 25 payments
  5. Paradise Ultrasound Renal Denervation System $10,145 31 payments
  6. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $9,605 6 payments
  7. WATCHMAN WATCHMAN Pro_IC $6,409 7 payments
  8. AMPLATZER AMULET $4,920 52 payments
  9. PARADISE RENAL DENERVATION SYSTEM $4,142 17 payments
  10. GENERAL THERAPIES $2,400 1 payment
  11. Other $37,467 753 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 28 drugs

Part D claims

1,474

Median for Interventional Cardiology: 2,236

Drug cost

$239,756

Median for Interventional Cardiology: $380,412

Branded share of claims

31.2%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Entresto Sacubitril/Valsartan Brand 57 $90,724
Repatha Sureclick Evolocumab Brand 44 $42,172
Eliquis Apixaban Brand 42 $31,093
Xarelto Rivaroxaban Brand 24 $29,923
Brilinta Ticagrelor Brand 38 $25,724
Clonidine Generic 37 $5,137
Metoprolol Succinate Generic 177 $2,767
Ranolazine Er Ranolazine Brand 20 $1,809
Losartan Potassium Generic 114 $1,226
Isosorbide Mononitrate Er Isosorbide Mononitrate Brand 77 $1,215

The 10 drugs with the highest cost, of 28 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 103 billing codes

Paid by Medicare

$211,576

Medicare's payments for the services billed

Medicare patients

1,237

Average age 75

Services billed

3,248

624 women, 613 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 63%
Arthritis 62%
Atrial fibrillation 42%
Diabetes 40%
Heart failure 37%
Chronic kidney disease 31%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Repatha
$185 44 —
LEQVIO
$171 — —
XARELTO
$168 24 —
ELIQUIS
$55 42 —
ENTRESTO
$50 57 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

977 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record